Hepatitis represents a ubiquitous human health problem but effective therapies with limited side effects are still lacking. In this study, we investigated the effect and mechanism of TP-58, a novel thienopyridine derivative, on a murine fulminant hepatitis model induced by concanavalin A (ConA). We found TP-58 markedly alleviated ConA-caused liver injury and increased survival ratio of mice injected with a lethal dose of ConA. Oral administration of TP-58 significantly alleviated ConA-caused liver injury in mice by the reduction of serum aminotransferases and liver necrosis.The analysis of proinflammatory cytokines showed that TP-58 decreased both hepatic mRNA expressions and serum protein levels of TNF-α and IL-6. And the result from LPS-stimulated RAW 264.7 cells showed TP-58 suppressed the production of TNF-α, IL-6, and Nitro Oxide (NO) in the supernatant of LPS-stimulated RAW 264.7 cells. The study of activation of nuclear factor-κB (NF-κB) by electrophoretic mobility shift assay (EMSA) showed that TP-58 inhibited the activation of NF-κB both in vivo and in vitro. The inhibitory effect was also accompanied by a parallel reduction of IκB phosphorylation. These results indicate that TP-58 protects against liver injury by inhibition of the NF-κB-mediated inflammation and suggest a potential role of TP-58 against acute liver injury and other inflammatory diseases.
Introduction
Hepatic injury, caused by misdirected immune stimulation or infection of virus, is an acute inflammatory injury characterized by infiltration of inflammatory cells into liver and the production of proinflammatory cytokines 32 by these cells [1] . Therapies of hepatic injury have been wildly studied. However, effective drugs with limited side effects are still lacking and the precise mechanisms are not fully understood. Concanavalin A (ConA)-induced hepatitis is the mouse model of immune-mediated liver injury resembling viral and autoimmune hepatitis in humans [2] . It is characterized by markedly increased plasma levels of transaminase and infiltration of the liver with T cells, neutrophils, and macrophages, followed by apoptosis and necrosis of the hepatocytes [2, 3] . In this model, activities of T cells and macrophages (kuffer cells) induced by ConA have shown to be specifically important and various proinflammatory cytokines produced by the cells ,including IFN-γ, TNF-α, IL-1β, IL-6, and Nitro Oxide (NO), play essential roles for liver injury [3] [4] [5] .
TP-58 is a novel thienopyridine derivative (shown in Fig. 1A ) from the small molecular compound library of our own synthesis laboratory, has previously been shown an apparently anti-tumor activity in vitro [6] . In previous screening of anti-inflammatory agents, TP-58 presented the inhibitory effects on production of NO and TNF-α in the supernatant of LPS-stimulated murine macrophage cell line, RAW264.7 cells, suggesting a potential antiinflammatory activity.
The aim of this study was to analyze whether TP-58 is able to ameliorate liver injury in the murine fulminant hepatitis model induced by ConA and explore its possible mechanism.
Materials and Methods
Reagent TP-58 was synthesized with purity more than 99.5% in our lab, and dissolved in saline containing 10% Tween-80 (Sigma-Aldrich, St. Louis, USA). The structure and purity were identified by high performance liquid chromatography, a Q-TOF Premier Mass Spectrometer (Waters Micromass, Milford, USA) and Nuclear Magnetic Resonance (Bruker Avance 400 NMR system).
Establishment of a Murine Model with Hepatitis
Six to eight week-old female BALB/c mice were obtained from Western China Experimental Animal Center, Sichuan University, maintained under controlled conditions, and treated with humane care according to National Institutes of Health Guidelines of China. ConA is dissolved in saline and administered in a total volume of 200 µl per mouse for i.v. injections. Female BALB/c mice were weighed and randomized into treatment groups of 10 animals and normal control group of 6 animals. The acute hepatitis in mice was induced by a single intravenous injection of 15 mg/kg of ConA [7] . For drug treatment, two concentrations of TP-58, 50 and 250 mg/kg, respectively were administered by gavage after 0.5 hour of ConA i.v. injection. 500 µg/kg dexamethasone (Sigma, USA) was administered intraperitoneally 1 hour before ConA administration as a positive control [7] . Mice were sacrificed 20 hours post injection of ConA, then liver and serum samples were collected. To examine survival rate, mice were challenged with a 30 mg/kg of lethal dose of ConA and pretreated with 250 mg/kg TP-58 at 1 hour prior to ConA injection. Then mice were monitored every 2 hours for the survival.
Analysis of liver enzymes and quantification of cytokine concentrations in plasma samples or cells supernatants
Liver injury was measured by serum enzyme activities of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) by the Chemical Lab in the National Chengdu Center for Safety Evaluation of Drugs. The concentrations of TNF-α and IL-6 in plasma samples or RAW264.7 cells supernatants were analyzed by ELISA using commercially available kits (JingMei, China) according to the manufacturer's instruction.
Histology
Liver sections were fixed in 10% formalin, embedded in paraffin, cut into 4-µm sections, strained with hematoxylin-eosin [8] to evaluate liver injury under optical microscope.
RNA Isolation and RT-PCR
Total RNA was isolated from liver tissue using TRIzol reagent (Invitrogen, USA) according to the manufacturer's instructions. The concentration of RNA was determined and cDNA was generated using total RNA with the Reverse Transcriptase kit (TaKaRa, Japan). For amplification of the desired cDNA, the specific primers (Table 1) were used as described previously [9] . RT-PCR products were visualized through 1% agarose gels containing ethidium bromide by electrophoresis.
EMSA
After nuclear extracts were prepared according to the method of Hentze [10], electrophoretic mobility shift assays (EMSA) were performed as previously described [11] . The oligonucleotide probes used for this experiment were sense, 5'-AGT TGA GGG GAC TTT CCC AG G C-3'; anti sense, 5'-GCC TGG GAA AGT CCC CTC AAC T-3'; and NF-κB mutant, sense 5'-AGT TGA GGC GAC TTT CCC AGG C-3', anti-sense, 5'-GCC TGG GAA AGT CGC CTC AAC T-3'.
Western Blot
Twenty micrograms of protein from murine liver tissue or RAW264.7 cells was mixed with an equal volume of 2×SDS sample buffer boiled for 5 min and then separated by 10% SDSpolyacrylamide gel electrophoresis. After electrophoresis, proteins were transferred to PVDF membrane. Membranes were incubated with an anti-IκB antibody or an anti-phosphorylated IκB antibody (Cell Signaling,USA) or an anti-GAPDH antibody (Sigma, USA). An anti-p-AKT (Ser-473) antibody (Cell Signaling,USA) was used for p-AKT determination, an anti-AKT (Cell Signaling) and an anti-GAPHD antibody (Sigma, USA) were used respectively for determination of the total AKT and GAPDH. The protein signal was quantified by scanning densitometry using an image analysis system (BioRad).
Cell culture and Nitrite assay
Raw264.7, a mouse macrophage-like cell line was obtained from the American Type Culture Collection (Cryosite, Lane Cove, NSW, Australia). These cells were grown in DMEM containing 10% FBS, 100 units/ml penicillin, and 100 pg/ml streptomycin in a 95% air, 5% CO2 humidified atmosphere at 37 °C. Raw 264.7 cells were plated at 2×10 
Statistical analysis
Statistical analysis was performed with the SPSS software system (SPSS for Windows, version 13.0; SPSS Inc, Chicago, IL). Parametric data were statistically analyzed by the Student's t test or one-way ANOVA followed by post hoc tests when appropriate. Differences in Non-parametric data were evaluated by the Mann-Whitney U test. Survival curves were statistically analyzed using Kaplan-Meier test. Data were expressed as means ± SD. A significant difference was defined as p < 0.05.
Results

Therapeutic effects of TP-58 on the ConAinduced acute hepatic injury model
ConA injection causes hepatic injury, including hepatocytic necrosis, steatosis and inflammatory infiltration. To estimate the efficacy of TP-58 in acute hepatic injury, we treated mice with 50 mg/kg and 250 mg/kg TP-58 respectively after 0.5 hour of intravenous injection of ConA and sacrificed mice at 20 hours. Treatment of TP-58 markedly alleviated ConA-caused liver injury in mice, as indicated by the reduction of serum aminotransferase (Table 2 ). Higher dose of TP-58 (250 mg/kg) inhibited the ConA-induced transaminase more significantly than the lower dose of 50 mg/kg.
Routine histopathology confirmed that ConAinduced hepatic injury consisted of degenerative hepatocellular swelling and cytoplasmic vacuolization, centrilobular hepatic necrosis and slight to mild periportal infiltrates of mononuclear inflammatory cells (Fig. 1B) . Mice treated with either 50 mg/kg or 250 mg/kg of TP-58 significantly reduced the severity of hepatic necrosis and vacuolization compared with ConA-treated animals as shown in Fig. 1B . Histological scores of centrilobular necrosis for individual animals showed that ConA induced a higher score of centrilobular necrosis (3.09±0.59) and with the 50 mg/kg or 250 mg/kg of TP-58 treatment, the scores of centrilobular necrosis significantly and respectively decreased to 2.33±0.41 and 1.42±0.73 (Fig.  1C) .
As reduced liver damage correlated with enhanced survival, we also studied whether TP-58 pretreatment elevated the survival rate of mice which were challenged with 30mg/kg of ConA, a leathal dose reported by previous research [13] . Mice were observed every 2 hours for survival after ConA injection and the results showed that animals pretreated for 1 hour with TP-58 produced a statistically significant increased survival rate (Fig. 1D) . Thirty percent of the animals pretreated with the TP-58 survived greater than 1 week compared with 0% for animals only with ConA administration.
These results indicated that TP-58 was effective on protecting mice from hepatic injury induced by ConA.
TP-58 inhibits the production of proinflammatory cytokines
Proinflammatory cytokines play an important role in both human and animal model of hepatitis. These factors are not only indispensable for the onset of hepatitis by their cooperative signaling but also directly damage hepatocytes [14] . We analyzed the effects of TP-58 on proinflammatory cytokines. As shown in Fig. 2A , ConA challenge led to elevation of the expressions of mRNA of the IFN-γ, TNF-α, IL-1β, IL-6 and iNOS at 2 hours after ConA injection, compared with normal control group. Administration of TP-58 into ConA injected mice resulted in significant suppression of the mRNA levels of TNF-α, IL-1β, IL-6 and iNOS, but not IFN-γ (Fig. 2A) . We also measured the levels of TNF-α and IL-6 in the serum of ConA-induced mice. As shown in Fig. 2B and C, TP-58 treatment significantly reduced the levels of TNF-α (Fig. 2B ) and IL-6 (Fig. 2C) in serum of ConAinduced mice.
We further investigated the effect of TP-58 in LPSstimulated RAW 264.7 cells. With LPS stimulation, the levels of TNF-α and IL-6 in the supernatant of RAW 264.7 cells were raised, while TP-58 significantly decreased the levels of TNF-α (Fig. 2D ) and IL-6 (Fig.  2E ) in the supernatant of LPS-stimulated RAW 264.7 cells. We also determined the production of NO in the supernatant of LPS-stimulated RAW 264.7 cells by measuring the amount of nitrite, a stable metabolite of NO. During the 18 hours incubation, RAW264.7 macrophages in the resting state produced 6.54±0.48 µM nitrite. When LPS (1 µg/ml) was added, the nitrite was dramatically increased to 18.22±1.69 µM (Fig. 2F) . Pretreatment with TP-58 inhibited LPS induced NO production in a concentration-dependent manner (Fig. 2F) . These results indicated that TP-58 suppressed production of cytokines during the inflammation, which might protect the liver from injury.
TP-58 suppresses NF-κB activation
As NF-κB plays a key role in regulating inflammatory responses, to further explore the mechanism of TP-58 in anti-inflammation, we analyzed the activation of NF-κB through electrophoretic mobility shift assay (EMSA) in the ConA-induced acute hepatic injury mice with 50 mg/kg or 250 mg/kg of TP-58 treatment. As shown in Fig. 3A , a specific NF-κB DNA binding activity was induced in mouse liver at 1 hour of ConA injection, whereas TP-58 pretreatment significantly inhibited the activation of NF-κB (Fig. 3A) . The specificity of the Mice were injected with ConA 1 hour after TP-58 50 mg/kg and TP-58 250 mg/kg administration then were sacrificed 20 hours later. B. The phosphorylation state of IκB in vitro was determined by Western blot. RAW264.7 macrophage cells were treated with increasing TP-58 concentrations (from 1.25 µM to 10 µM) for 1hour followed by LPS (1 µg/ml) for 30min. C. Western blot of hepatic phospho-AKT. Mice were injected with ConA 1 hour after TP-58 50 mg/kg and TP-58 250 mg/kg administration then were sacrificed 20 hours later. Representative results were from 3 independent experiments. Data are means ± SD;* p<0.05 vs ConA.
NF-κB/probe interaction was confirmed by addition of an excess of unlabeled "cold" probe [15] . The inhibitory activation of NF-κB by TP-58 was also identified in LPS stimulation in raw264.7 macrophage cells (Fig. 3B) . As shown in Fig. 3B , LPS inducing activation of NF-κB DNA binding was most pronounced at 30 minutes after administration of LPS, which was significantly inhibited by TP-58 pre-exposure (Fig. 3B) . These results indicated that TP-58 interfering the process of inflammation by inhibiting the NF-κB pathways.
TP-58 inhibits IκB Phosphorylation
Phosphorylation of the inhibitory protein IκB enables nuclear translocation and DNA binding of NF-κB [16] . To gain further insight into the mechanism of TP-58 mediated regulation of NF-κB, we studied the change of IκB phosphorylation. As shown in Fig. 4A and Fig. 4B , TP-58 significantly inhibited IκB phosphorylation of both in the murine hepatitis model induced by ConA (Fig. 4A ) and in the supernatant of LPS-stimulated RAW 264.7 cells (Fig. 4B) .
TP-58 does not inhibit AKT Phosphorylation
AKT signaling is an important pathway related with cell survival/proliferation, and is also relative to migration of immunocyte [17] . We observed whether the suppressed liver injury upon TP-58 was also associated with AKT signaling. As shown in Fig. 4C , ConA actually enhanced AKT phosphorylation of mouse liver, but which was not inhibited by TP-58 administration. Instead, we found a (Fig. 4C) .
Toxicity of TP-58
To examine the toxicity of TP-58, mice were sacrificed 4 weeks after consecutively oral administration of 250 mg/kg TP-58. Then histopathological analysis of several organs and serum biochemical parameters were analyzed. As shown in Fig. 5 , we found no significant difference of histopathology and serum transaminase between control group and TP-58 group (Fig. 5) .
Disscussion
In our study, TP-58 markedly suppressed ConAcaused liver injury and increased survival ratio of mice challenged with a lethal dose of ConA. The administration of TP-58 significantly alleviated ConA-caused liver injury in mice by the reduction of serum aminotransferases and liver necrosis. The analysis of proinflammatory cytokines revealed that TP-58 decreased both hepatic mRNA expressions and serum protein levels of TNF-α and IL-6. And the result from LPS-stimulated RAW 264.7 cells showed TP-58 suppressed the production of TNF-α, IL-6, and NO in the supernatant of LPS-stimulated RAW 264.7 cells. TP-58 also inhibited the activation of NF-κB both in the murine hepatitis model induced by ConA and in LPS-stimulated RAW 264.7 cells. The inhibitory effect was also accompanied by a parallel reduction of IκB phosphorylation.
Thienopyridine derivatives have been used as the inhibitor of the platelet adenosine diphosphate receptor in cardiovascular diseases [18] and also recently reported to be effective on antitumor and inhibiting inflammation [6, 19] . Our current study identified the role of TP-58, the novel thienopyridine derivative, which protected mice from ConA-induced fulminate hepatitis by suppressing inflammation.
Proinflammatory cytokines play critical roles in the process of inflammations and the increased production of IFN-γ, TNF-α, IL-1β, IL-6 and NO has been reported to be associated with both human hepatitis and ConAinduced liver injury [20] [21] [22] [23] [24] . In current study, ConA injection caused massively intrahepatic increases of mRNAs levels of INF-γ, TNF-α, IL-1β, IL-6 and iNOS in 2 hours of ConA administration, which was consistent with previous reports [6, [25] [26] [27] . TP-58 clearly inhibited the serum protein levels of TNF-α and IL-6 and the intrahepatic mRNAs expressions of TNF-α, IL-1β, IL-6 and iNOS, but not INF-γ, a T cell-produced cytokine in ConA-induced mice. The in vitro experiments further identified TP-58 suppressed production of NO, TNF-α and IL-6 in LPS-stimulated RAW264.7 macrophages. The results suggest that TP-58 may protect mice from ConAinduced hepatitis by inhibition of proinflammatory cytokines. The production of inflammatory mediators has been known to mainly depend on the activation of transcription factor NF-κB [7, 28] . In the process of liver injury, activation of NF-κB in the resident liver macrophages, ie, Kupffer cells, leads to increased expression of proinflammatory cytokines such as iNOS, TNF-α and IL-6, leading to inflammation and liver failure [29] . Based on its essential role in inflammation, NF-κB has been an important target for inflammatory diseases. Several reports have proved that inhibition of NF-κB is able to improve survival and reduced liver injury in ConAinduced mice [30, 31] . NF-κB presents in the cytoplasm as a complex with inactive IκB in unstimulated cells. In response to stimuli signal, IκB is phosphorylated and causing its subsequent degradation, thus leading to NF-κB to release from IκB and enter into the nucleus, where it activates the transcription of NF-κB-responsible gene such as TNF-α and IL-6 [28, 32] . Our study showed that TP-58 administration decreased the phosphorylation of IκB and inhibited the activation of NF-κB both in the murine hepatitis model induced by ConA and in LPS-stimulated RAW 264.7 cells. These results supported TP-58 protecting mice from ConA-induced liver injury by inhibiting NF-κB pathways. Although we found that ConA-induced liver injury also presented an enhanced phosphorylation of AKT (Fig. 4C) , which is associated with the cellular survival [33] , administration of TP-58 led to little change of phosphorylation of AKT, indicating TP-58 ameliorated ConA-induced liver injury mainly by interfering the NF-κB pathways, but not AKT signaling. Tina Morwick et al. have reported that thienopyridine derivatives are the potent IKK-β inhibitors, which reduce the activation of NF-κB by inhibition of IKKβ [34] . So it is worthy to identify if TP-58 also reduces NF-κB by inhibition of IKKβ in the future study.
In conclusion, this study firstly reports the effects and mechanisms of TP-58 on ameliorating liver injury by suppressing inflammation, suggesting that TP-58 might define an anti-inflammatory role in immunologically mediated diseases and might even set the new stage for therapy of inflammatory liver diseases.
